In recent years, inhibitors of the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway have received much attention as HCC immunotherapies (4–6). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.